Soluble activin receptor type IIB increases forward pulling tension in the mdx mouse

Area of Science:

• Biomedical research
• Muscle physiology
• Duchenne muscular dystrophy

Background:

• Investigated RAP-031, a soluble activin receptor type IIB (ActRIIB), and ursodeoxycholic acid (UDCA), an NF-κB inhibitor.
• Focused on their effects on whole body strength in mdx mice, a model for Duchenne muscular dystrophy.

Purpose of the Study:

• To evaluate the efficacy of myostatin inhibition using RAP-031.
• To assess the synergistic effects of combining RAP-031 with UDCA on muscle strength in mdx mice.

Main Methods:

• Utilized the whole body tension (WBT) method to measure forward pulling tension (FPT) in mdx mice.
• Administered RAP-031 alone and in combination with UDCA.

Main Results:

• RAP-031 significantly increased body mass (41%) and FPT (42.5%) but did not alter FPT normalized for body mass.
• Coadministration of RAP-031 and UDCA resulted in enhanced FPT increases associated with improved WBT.

Conclusions:

• Myostatin inhibition increases muscle mass but does not overcome the inherent weakness in dystrophic muscle.
• Combination therapy with an NF-κB inhibitor potentiates the benefits of myostatin inhibition for improving muscle strength in mdx mice.